European Pharmaceutical Review

JULY 5, 2023

Having been originally published in 2007, then revised in 2013, this latest 2023 edition addresses evolving standards and container types. According the PDA, the standardised quality criteria in TR 43 are intended as a guidance overview for container manufacturers and for incoming container acceptance inspection at pharmaceutical companies.

Packaging 96

Packaging Documentation Pharmaceutical Companies Pharmaceutical Companies 96

pharmaphorum

AUGUST 23, 2021

The possibility of data being shared with third-parties including academic researchers and pharmaceutical companies raised concerns about whether the public is aware that they stand to lose control of private information on their physical, mental and sexual health. Now that’s been set back indefinitely. survey conducted in July.

Medical Records 89

Medical Records Documentation Pharmaceutical Companies Pharmaceutical Companies 89

European Pharmaceutical Review

SEPTEMBER 22, 2022

Dr Maier has over 25 years of experience in drug development and commercialisation at pharmaceutical companies in Europe, Canada, the United States and Asia. 2013 Oct; 48(10): 943–953. Published online 2013 Jul 2. Mayer-Hamblett N, Rosenfeld M, Treggiari MM et al. Pediatr Pulmonol. doi: 1002/ppul.22693. Thompson, LA.

Pharmaceutical Companies 122

Pharmaceutical Companies Pharmaceutical Companies FDA Documentation 122

ISPE

MAY 9, 2023

In an era when the world is accelerating the development of drugs and targeted medicines using innovative technologies, pharmaceutical companies still face registration hurdles for well-characterized molecules because of redundant or additional local regulatory requirements.

Documentation 52

Documentation Packaging Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

MAY 14, 2021

Practically though, there are risks of additional processes and requirements (and expense) for pharmaceutical companies. It is also possible that companies may prefer to enter the EU market through the EMA process and avoid additional processes involving the MHRA and NICE.

Documentation 59

Documentation Pharmaceutical Companies Pharmaceutical Companies 59

Pharmaceutical Technology

OCTOBER 5, 2022

These, along with other similar claims, meant Biogen owed potential damages of $1,036,900,151 to the US and the various States, as per court documents. Ferry describes a popular solution among pharmaceutical companies. The $900 million dollar settlement was previously announced in June but has only been finalized this month.

Documentation 59

Documentation Pharmaceutical Companies Pharmaceutical Companies FDA 59

The People's Pharmacy

MAY 8, 2023

There have been problems with records in the past: deceit, falsification of documents and even outright fraud. Since the start of 2013, pharmaceutical companies based in the U.S. But a whistleblower at the company reported that some of the scientists there were falsifying data. Carcinogens in Blood Pressure Meds?

FDA 72

FDA Pharmaceutical Companies Pharmaceutical Companies Medical Schools 72